SCHEMBL485352

SCHEMBL485352

CC(C)(C)OC(=O)N1CCC2(CCN(c3ncccn3)CC2)C1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.62
GPR119 Q8TDV5 1/20 0.62
CYP11B2 P19099 1/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 6/20 0.58
TSHR P16473 2/20 0.58
CYP2C9 P11712 5/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPK1 P28482 2/20 0.54
CYP2D6 P10635 8/20 0.53
MAPT P10636 1/20 0.52
CYP1A2 P05177 4/20 0.51
CYP2C19 P33261 3/20 0.51
USP2 O75604 2/20 0.51
HPGD P15428 2/20 0.50
SCD5 Q86SK9 1/20 0.49
HIF1A Q16665 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23108168 0.92 GPR119 (0.58) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL23108169 0.90 HSD17B10 (0.61) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL23742297 0.86 CYP11B2 (0.56) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL484915 0.85 HSD17B10 (0.65) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL484867 0.84 CYP11B2 (0.54) CYP3A4GPR119CYP11B2HSD17B10TSHR
SCHEMBL15570718 0.84 GPR119 (0.60) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL12964579 0.82 GPR119 (0.77) CYP3A4GPR119HSD17B10SMN1; SMN2MAPT
SCHEMBL29461446 0.82 HSD17B10 (0.69) CYP3A4GPR119CYP11B2MEN1KMT2A
SCHEMBL484102 0.81 HIF1A (0.63) CYP3A4CYP11B2MEN1KMT2AHSD17B10
SCHEMBL28614518 0.81 CYP11B2 (0.51) CYP3A4GPR119CYP11B2MAPTSCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 EP disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN CYP3A4 3781/4885GPR119 206/4885CYP11B2 2150/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN CYP3A4 3781/4885GPR119 206/4885CYP11B2 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.